drugset / Trial / NCT00928811
Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is undertaken to explore the safety of using Simulect at monthly dose intervals to reduce the need of high dose/level CNI's such as Prograf.
Timeline
- Start
- 2009-05
- Primary completion
- 2010-04
- Completion
- 2010-04
Outcome
Outcome not reported
Stopped: “Investigator left University 04/2010”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basiliximab | Monoclonal antibody | 20 mg | Intravenous |
| Subject | Basiliximab | Monoclonal antibody | 40 mg | Intravenous |